Development of ELISAs in the context of a vaccine program against Candida albicans
In vitro/ex vivo testing Antibacterial and antifungal
Background of Elisa Based assays model development
• In addition to viruses and bacteria, fungi are the other organisms, that are either equally or more dangerous to human health.
• Vaccines against invasive pathogens represent a major step forward in combating infectious diseases.
• There is an increasing interest in developing safe and potent immune-based therapeutics to tackle fungal diseases. In this context, vaccine design and its development have a priority.
Objectives of the model
• To develop customized ELISAs to quantify antibodies specific for 5 different antigens used as vaccine candidates against Candida albicans.
Our approach at Vibiosphen
• Exhaustive state of the art of the different experimental parameters that required to be optimized for the development of the assay
• Optimization of each parameter
• Update our client after each step of the optimization
• Use of the developed ELISAs to screen successive vaccination campaigns
• Rapid results delivery : priority mission for two members of the company to perform the tests
Outcomes of Elisa Based assays model
• Determination of antibodies titers specific for 5 different antigens in serums of immunized mice, rabbits and rats.
• This brought insights into the most promising vaccination regimens which were then used for the design of the further campaign vaccinations.
• The vaccine program entered phase I clinical trial.
Why Choose Vibiosphen?
• Proven expertise in preclinical research
• Flexible and customized study designs adapted to sponsor requirements (see downloads available as example)
• Advanced facilities to ensure reliable and reproducible results (BSL2 and BSL3)
• Strong collaborations with pharmaceutical companies, biotech firms, and academic partners
Vibiosphen combines scientific excellence with industry know-how to deliver actionable preclinical data that drive innovation in infectious disease therapeutics.
Contact Us
If you are developing new treatments or vaccines, Vibiosphen can help accelerate your research.
Contact us today to discuss your project and explore how our Pharmacokinetics models can support your development strategy. We will be pleased to facilitate your project by providing a customized study design to your project objectives.